Loading company…
Opna Bio develops cancer therapies.
Opna Bio is a clinical-stage biopharmaceutical company developing oncology drugs. Its lead product, OPN-2853, is in a Phase 1/2 trial with ruxolitinib for myelofibrosis. The company is based in Switzerland and also had a US office as of 2022. It raised USD 38 million in Series A funding in November 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in